Challenges in the clinical utility of the serum test for HER2 ECD

Biochimica et Biophysica Acta - Reviews on Cancer

Volumn 1826, Issue 1, 2012, Pages 199-208

  Lam, Lian ^a   McAndrew, Nicholas ^a   Yee, Marla ^a   Fu, Ting ^a   Tchou, Julia C ^b   Zhang, Hongtao ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Detection; Extracellular domain (ECD); HER2; Serum biomarker; Targeted therapy

Indexed keywords

ANTINEOPLASTIC AGENT; BIOLOGICAL MARKER; CYCLOPHOSPHAMIDE; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIRUBICIN; LAPATINIB; LETROZOLE; PACLITAXEL; PERTUZUMAB; TAMOXIFEN; TRASTUZUMAB;

ADJUVANT THERAPY; AUTOLOGOUS STEM CELL TRANSPLANTATION; AXILLARY LYMPH NODE; BLOOD ANALYSIS; BREAST CANCER; BREAST SURGERY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER STAGING; CHEMOLUMINESCENCE; CLINICAL PRACTICE; DIAGNOSTIC TEST APPROVAL; DIAGNOSTIC VALUE; DISEASE COURSE; DRUG DOSE COMPARISON; DRUG TARGETING; ENZYME IMMUNOASSAY; ENZYME LINKED IMMUNOSORBENT ASSAY; FLUORESCENCE IN SITU HYBRIDIZATION; FOOD AND DRUG ADMINISTRATION; GENE OVEREXPRESSION; HUMAN; IMMUNOASSAY; IMMUNOHISTOCHEMISTRY; LYMPH NODE DISSECTION; MASTECTOMY; ONCOGENE NEU; OVERALL SURVIVAL; PATIENT MONITORING; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; PROTEIN DOMAIN; REFERENCE VALUE; REVIEW; SCREENING TEST; SENSITIVITY AND SPECIFICITY; TREATMENT OUTCOME; TREATMENT RESPONSE;

BREAST NEOPLASMS; HUMANS; RECEPTOR, ERBB-2; TUMOR MARKERS, BIOLOGICAL;

EID: 84860381261     PISSN: 0304419X     EISSN: 18792561     Source Type: Journal    
DOI: 10.1016/j.bbcan.2012.03.012     Document Type: Review

References (93)

1. Quaranta M., Daniele A., Coviello M., Savonarola A., Abbate I., Venneri M.T., Paradiso A., Stea B., Zito A., Labriola A., Schittulli F. c-erbB-2 protein level in tissue and sera of breast cancer patients: a possibly useful clinical correlation. Tumori 2006, 92:311-317.
2. Willsher P.C., Beaver J., Pinder S., Bell J.A., Ellis I.O., Blamey R.W., Robertson J.F. Prognostic significance of serum c-erbB-2 protein in breast cancer patients. Breast Cancer Res. Treat. 1996, 40:251-255.
3. Cheung K.L., Pinder S.E., Paish C., Sadozye A.H., Chan S.Y., Evans A.J., Blamey R.W., Robertson J.F. The role of blood tumor marker measurement (using a biochemical index score and c-erbB2) in directing chemotherapy in metastatic breast cancer. Int. J. Biol. Markers 2000, 15:203-209.
4. Breuer B., De Vivo I., Luo J.C., Smith S., Pincus M.R., Tatum A.H., Daucher J., Minick C.R., Miller D.G., Nowak E.J., et al. erbB-2 and myc oncoproteins in sera and tumors of breast cancer patients. Cancer Epidemiol. Biomarkers Prev. 1994, 3:63-66.
5. Asgeirsson K.S., Agrawal A., Allen C., Hitch A., Ellis I.O., Chapman C., Cheung K.L., Robertson J.F. Serum epidermal growth factor receptor and HER2 expression in primary and metastatic breast cancer patients. Breast Cancer Res. 2007, 9:R75.
6. Slamon D.J., Godolphin W., Jones L.A., Holt J.A., Wong S.G., Keith D.E., Levin W.J., Stuart S.G., Udove J., Ullrich A. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 1989, 244:707-712.
7. Cohen J.A., Weiner D.B., More K.F., Kokai Y., Williams W.V., Maguire H.C., LiVolsi V.A., Greene M.I. Expression pattern of the neu (NGL) gene-encoded growth factor receptor protein (p185neu) in normal and transformed epithelial tissues of the digestive tract. Oncogene 1989, 4:81-88.
8. Williams T.M., Weiner D.B., Greene M.I., Maguire H.C. Expression of c-erbB-2 in human pancreatic adenocarcinomas. Pathobiology 1991, 59:46-52.
9. Andersen T.I., Paus E., Nesland J.M., McKenzie S.J., Borresen A.L. Detection of c-erbB-2 related protein in sera from breast cancer patients. Relationship to ERBB2 gene amplification and c-erbB-2 protein overexpression in tumour. Acta Oncol. 1995, 34:499-504.
10. Schechter A.L., Stern D.F., Vaidyanathan L., Decker S.J., Drebin J.A., Greene M.I., Weinberg R.A. The neu oncogene: an erb-B-related gene encoding a 185,000-Mr tumour antigen. Nature 1984, 312:513-516.
11. Shih C., Shilo B.Z., Goldfarb M.P., Dannenberg A., Weinberg R.A. Passage of phenotypes of chemically transformed cells via transfection of DNA and chromatin. Proc. Natl. Acad. Sci. U. S. A. 1979, 76:5714-5718.
12. Garoufali A., Kyriakou F., Kountourakis P., Yioti I., Malliou S., Nikaki A., Kardara E., Frangos I., Koumna S., Baziotis N., Scorilas A., Ardavanis A. Extracellular domain of HER2: a useful marker for the initial workup and follow-up of HER2-positive breast cancer. J. BUON 2008, 13:409-413.
13. Colomer R., Montero S., Lluch A., Ojeda B., Barnadas A., Casado A., Massuti B., Cortes-Funes H., Lloveras B. Circulating HER2 extracellular domain and resistance to chemotherapy in advanced breast cancer. Clin. Cancer Res. 2000, 6:2356-2362.
14. Sugano K., Ushiama M., Fukutomi T., Tsuda H., Kitoh T., Ohkura H. Combined measurement of the c-erbB-2 protein in breast carcinoma tissues and sera is useful as a sensitive tumor marker for monitoring tumor relapse. Int. J. Cancer 2000, 89:329-336.
15. Slamon D.J., Clark G.M., Wong S.G., Levin W.J., Ullrich A., McGuire W.L. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987, 235:177-182.
16. Krainer M., Brodowicz T., Zeillinger R., Wiltschke C., Scholten C., Seifert M., Kubista E., Zielinski C.C. Tissue expression and serum levels of HER-2/neu in patients with breast cancer. Oncology 1997, 54:475-481.
17. Ahmed N., Salsman V.S., Kew Y., Shaffer D., Powell S., Zhang Y.J., Grossman R.G., Heslop H.E., Gottschalk S. HER2-specific T cells target primary glioblastoma stem cells and induce regression of autologous experimental tumors. Clin. Cancer Res. 2010, 16:474-485.
18. Pallud C., Guinebretiere J.M., Guepratte S., Hacene K., Neumann R., Carney W., Pichon M.F. Tissue expression and serum levels of the oncoprotein HER-2/neu in 157 primary breast tumours. Anticancer Res. 2005, 25:1433-1440.
19. Ludovini V., Gori S., Colozza M., Pistola L., Rulli E., Floriani I., Pacifico E., Tofanetti F.R., Sidoni A., Basurto C., Rulli A., Crino L. Evaluation of serum HER2 extracellular domain in early breast cancer patients: correlation with clinicopathological parameters and survival. Ann. Oncol. 2008, 19:883-890.
20. Farzadnia M., Meibodi N.T., Shandiz F.H., Mahmoudi M., Bahar M.M., Memar B., Amoian S., Maroozi F., Moheghi N. Evaluation of HER2/neu oncoprotein in serum and tissue samples of women with breast cancer: correlation with clinicopathological parameters. Breast 2010, 19:489-492.
21. Allison M. The HER2 testing conundrum. Nat. Biotechnol. 2010, 28:117-119.
22. Wolff A.C., Hammond M.E., Schwartz J.N., Hagerty K.L., Allred D.C., Cote R.J., Dowsett M., Fitzgibbons P.L., Hanna W.M., Langer A., McShane L.M., Paik S., Pegram M.D., Perez E.A., Press M.F., Rhodes A., Sturgeon C., Taube S.E., Tubbs R., Vance G.H., van de Vijver M., Wheeler T.M., Hayes D.F. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J. Clin. Oncol. 2007, 25:118-145.
23. Paik S., Bryant J., Tan-Chiu E., Romond E., Hiller W., Park K., Brown A., Yothers G., Anderson S., Smith R., Wickerham D.L., Wolmark N. Real-world performance of HER2 testing-National Surgical Adjuvant Breast and Bowel Project experience. J. Natl. Cancer Inst. 2002, 94:852-854.
24. Sui W., Ou M., Chen J., Wan Y., Peng H., Qi M., Huang H., Dai Y. Comparison of immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH) assessment for Her-2 status in breast cancer. World J. Surg. Oncol. 2009, 7:83.
25. Sauter G., Lee J., Bartlett J.M., Slamon D.J., Press M.F. Guidelines for human epidermal growth factor receptor 2 testing: biologic and methodologic considerations. J. Clin. Oncol. 2009, 27:1323-1333.
26. Perez E.A., Suman V.J., Davidson N.E., Martino S., Kaufman P.A., Lingle W.L., Flynn P.J., Ingle J.N., Visscher D., Jenkins R.B. HER2 testing by local, central, and reference laboratories in specimens from the North Central Cancer Treatment Group N9831 intergroup adjuvant trial. J. Clin. Oncol. 2006, 24:3032-3038.
27. Kong S.Y., Nam B.H., Lee K.S., Kwon Y., Lee E.S., Seong M.W., Lee do H., Ro J. Predicting tissue HER2 status using serum HER2 levels in patients with metastatic breast cancer. Clin. Chem. 2006, 52:1510-1515.
28. Fornier M.N., Seidman A.D., Schwartz M.K., Ghani F., Thiel R., Norton L., Hudis C. Serum HER2 extracellular domain in metastatic breast cancer patients treated with weekly trastuzumab and paclitaxel: association with HER2 status by immunohistochemistry and fluorescence in situ hybridization and with response rate. Ann. Oncol. 2005, 16:234-239.
29. Muller V., Witzel I., Luck H.J., Kohler G., von Minckwitz G., Mobus V., Sattler D., Wilczak W., Loning T., Janicke F., Pantel K., Thomssen C. Prognostic and predictive impact of the HER-2/ neu extracellular domain (ECD) in the serum of patients treated with chemotherapy for metastatic breast cancer. Breast Cancer Res. Treat. 2004, 86:9-18.
30. Codony-Servat J., Albanell J., Lopez-Talavera J.C., Arribas J., Baselga J. Cleavage of the HER2 ectodomain is a pervanadate-activable process that is inhibited by the tissue inhibitor of metalloproteases-1 in breast cancer cells. Cancer Res. 1999, 59:1196-1201.
31. Liu P.C., Liu X., Li Y., Covington M., Wynn R., Huber R., Hillman M., Yang G., Ellis D., Marando C., Katiyar K., Bradley J., Abremski K., Stow M., Rupar M., Zhuo J., Li Y.L., Lin Q., Burns D., Xu M., Zhang C., Qian D.Q., He C., Sharief V., Weng L., Agrios C., Shi E., Metcalf B., Newton R., Friedman S., Yao W., Scherle P., Hollis G., Burn T.C. Identification of ADAM10 as a major source of HER2 ectodomain sheddase activity in HER2 overexpressing breast cancer cells. Cancer Biol. Ther. 2006, 5:657-664.
32. Hayes D.F., Yamauchi H., Broadwater G., Cirrincione C.T., Rodrigue S.P., Berry D.A., Younger J., Panasci L.L., Millard F., Duggan D.B., Norton L., Henderson I.C. Circulating HER-2/erbB-2/c-neu (HER-2) extracellular domain as a prognostic factor in patients with metastatic breast cancer: Cancer and Leukemia Group B Study 8662. Clin. Cancer Res. 2001, 7:2703-2711.
33. Molina R., Jo J., Filella X., Zanon G., Pahisa J., Munoz M., Farrus B., Latre M.L., Gimenez N., Hage M., Estape J., Ballesta A.M. C-erbB-2 oncoprotein in the sera and tissue of patients with breast cancer. Utility in prognosis. Anticancer Res. 1996, 16:2295-2300.
34. Streckfus C., Bigler L., Dellinger T., Dai X., Kingman A., Thigpen J.T. The presence of soluble c-erbB-2 in saliva and serum among women with breast carcinoma: a preliminary study. Clin. Cancer Res. 2000, 6:2363-2370.
35. Kong S.Y., Kang J.H., Kwon Y., Kang H.S., Chung K.W., Kang S.H., Lee D.H., Ro J., Lee E.S. Serum HER-2 concentration in patients with primary breast cancer. J. Clin. Pathol. 2006, 59:373-376.
36. James R., Thriveni K., Ramaswamy G., Krishnamoorthy L., Mukherjee G., Deshmane P.V., Bapsy P. EVALUATION OF IMMUNOHISTOCHEMISTRY AND ENZYME LINKED IMMUNOSORBENT ASSAY FOR HER-2/NEU EXPRESSION IN BREAST CARCINOMA. Indian J. Clin. Biochem. 2008, 23:345-351.
37. Kuroda N., Kontani K., Kajikawa T., Taminato T. Study of the measurement of serum extracellular domain of HER-2/neu protein with CLIA method. Rinsho Byori 2010, 58:541-552.
38. Classen S., Kopp R., Possinger K., Weidenhagen R., Eiermann W., Wilmanns W. Clinical relevance of soluble c-erbB-2 for patients with metastatic breast cancer predicting the response to second-line hormone or chemotherapy. Tumour Biol. 2002, 23:70-75.
39. Narita T., Funahashi H., Satoh Y., Takagi H. C-erbB-2 protein in the sera of breast cancer patients. Breast Cancer Res. Treat. 1992, 24:97-102.
40. Harris L.N., Liotcheva V., Broadwater G., Ramirez M.J., Maimonis P., Anderson S., Everett T., Harpole D., Moore M.B., Berry D.A., Rizzeri D., Vredenburgh J.J., Bentley R.C. Comparison of methods of measuring HER-2 in metastatic breast cancer patients treated with high-dose chemotherapy. J. Clin. Oncol. 2001, 19:1698-1706.
41. Witzel I., Loibl S., von Minckwitz G., Mundhenke C., Huober J., Hanusch C., Henschen S., Hauschild M., Lantzsch T., Tesch H., Latos K., Just M., Hilfrich J., Barinoff J., Eulenburg C.Z., Roller M., Untch M., Muller V. Monitoring serum HER2 levels during neoadjuvant trastuzumab treatment within the GeparQuattro trial. Breast Cancer Res. Treat. 2010, 123:437-445.
42. Carney W.P., Neumann R., Lipton A., Leitzel K., Ali S., Price C.P. Potential clinical utility of serum HER-2/neu oncoprotein concentrations in patients with breast cancer. Clin. Chem. 2003, 49:1579-1598.
43. Kandl H., Seymour L., Bezwoda W.R. Soluble c-erbB-2 fragment in serum correlates with disease stage and predicts for shortened survival in patients with early-stage and advanced breast cancer. Br. J. Cancer 1994, 70:739-742.
44. Fontana X., Ferrari P., Namer M., Peysson R., Salanon C., Bussiere F. C-erb-B2 gene amplification and serum level of c-erb-B2 oncoprotein at primary breast cancer diagnosis. Anticancer Res. 1994, 14:2099-2104.
45. Todeschini P., Cocco E., Bellone S., Varughese J., Lin K., Carrara L., Guzzo F., Buza N., Hui P., Silasi D.A., Ratner E., Azodi M., Schwartz P.E., Rutherford T.J., Pecorelli S., Santin A.D. Her2/neu extracellular domain shedding in uterine serous carcinoma: implications for immunotherapy with trastuzumab. Br. J. Cancer 2011, 105:1176-1182.
46. Sorensen P.D., Jakobsen E.H., Langkjer S.T., Bokmand S., Ostergaard B., Olsen D.A., Madsen J.S., Brandslund I. Serum HER-2 concentrations for monitoring women with breast cancer in a routine oncology setting. Clin. Chem. Lab. Med. 2009, 47:1117-1123.
47. Carney W.P. Hidden HER-2/neu-positive breast cancer: how to maximize detection. IDrugs 2009, 12:238-242.
48. Zidan J., Dashkovsky I., Stayerman C., Basher W., Cozacov C., Hadary A. Comparison of HER-2 overexpression in primary breast cancer and metastatic sites and its effect on biological targeting therapy of metastatic disease. Br. J. Cancer 2005, 93:552-556.
49. Hoefnagel L.D., van de Vijver M.J., van Slooten H.J., Wesseling P., Wesseling J., Westenend P.J., Bart J., Seldenrijk C.A., Nagtegaal I.D., Oudejans J., van der Valk P., van der Groep P., de Vries E.G., van der Wall E., van Diest P.J. Receptor conversion in distant breast cancer metastases. Breast Cancer Res. 2010, 12:R75.
50. Fehm T., Maimonis P., Weitz S., Teramoto Y., Katalinic A., Jager W. Influence of circulating c-erbB-2 serum protein on response to adjuvant chemotherapy in node-positive breast cancer patients. Breast Cancer Res. Treat. 1997, 43:87-95.
51. Isola J.J., Holli K., Oksa H., Teramoto Y., Kallioniemi O.P. Elevated erbB-2 oncoprotein levels in preoperative and follow-up serum samples define an aggressive disease course in patients with breast cancer. Cancer 1994, 73:652-658.
52. Fehm T., Gebauer G., Jager W. Clinical utility of serial serum c-erbB-2 determinations in the follow-up of breast cancer patients. Breast Cancer Res. Treat. 2002, 75:97-106.
53. Vogel C.L., Cobleigh M.A., Tripathy D., Gutheil J.C., Harris L.N., Fehrenbacher L., Slamon D.J., Murphy M., Novotny W.F., Burchmore M., Shak S., Stewart S.J., Press M. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J. Clin. Oncol. 2002, 20:719-726.
54. Jensen B.V., Johansen J.S., Price P.A. High levels of serum HER-2/neu and YKL-40 independently reflect aggressiveness of metastatic breast cancer. Clin. Cancer Res. 2003, 9:4423-4434.
55. Imoto S., Wada N., Hasebe T., Ochiai A., Kitoh T. Serum c-erbB-2 protein is a useful marker for monitoring tumor recurrence of the breast. Int. J. Cancer 2007, 120:357-361.
56. Fehm T., Jager W., Kramer S., Sohn C., Solomayer E., Wallwiener D., Gebauer G. Prognostic significance of serum HER2 and CA 15-3 at the time of diagnosis of metastatic breast cancer. Anticancer Res. 2004, 24:1987-1992.
57. Lipton A., Ali S.M., Leitzel K., Demers L., Harvey H.A., Chaudri-Ross H.A., Brady C., Wyld P., Carney W. Serum HER-2/neu and response to the aromatase inhibitor letrozole versus tamoxifen. J. Clin. Oncol. 2003, 21:1967-1972.
58. Bewick M., Conlon M., Gerard S., Lee H., Parissenti A.M., Zhang L., Gluck S., Lafrenie R.M. HER-2 expression is a prognostic factor in patients with metastatic breast cancer treated with a combination of high-dose cyclophosphamide, mitoxantrone, paclitaxel and autologous blood stem cell support. Bone Marrow Transplant. 2001, 27:847-853.
59. Ali S.M., Leitzel K., Chinchilli V.M., Engle L., Demers L., Harvey H.A., Carney W., Allard J.W., Lipton A. Relationship of serum HER-2/neu and serum CA 15-3 in patients with metastatic breast cancer. Clin. Chem. 2002, 48:1314-1320.
60. Mansour O.A., Zekri A.R., Harvey J., Teramoto Y., el-Ahmady O. Tissue and serum c-erbB-2 and tissue EGFR in breast carcinoma: three years follow-up. Anticancer Res. 1997, 17:3101-3106.
61. Mazouni C., Hall A., Broglio K., Fritsche H., Andre F., Esteva F.J., Hortobagyi G.N., Buzdar A.U., Pusztai L., Cristofanilli M. Kinetics of serum HER-2/neu changes in patients with HER-2-positive primary breast cancer after initiation of primary chemotherapy. Cancer 2007, 109:496-501.
62. Lennon S., Barton C., Banken L., Gianni L., Marty M., Baselga J., Leyland-Jones B. Utility of serum HER2 extracellular domain assessment in clinical decision making: pooled analysis of four trials of trastuzumab in metastatic breast cancer. J. Clin. Oncol. 2009, 27:1685-1693.
63. Ali S.M., Carney W.P., Esteva F.J., Fornier M., Harris L., Kostler W.J., Lotz J.P., Luftner D., Pichon M.F., Lipton A. Serum HER-2/neu and relative resistance to trastuzumab-based therapy in patients with metastatic breast cancer. Cancer 2008, 113:1294-1301.
64. Baselga J., Tripathy D., Mendelsohn J., Baughman S., Benz C.C., Dantis L., Sklarin N.T., Seidman A.D., Hudis C.A., Moore J., Rosen P.P., Twaddell T., Henderson I.C., Norton L. Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer. J. Clin. Oncol. 1996, 14:737-744.
65. Lipton A., Leitzel K., Ali S.M., Carney W., Platek G., Steplewski K., Westlund R., Gagnon R., Martin A.M., Maltzman J. Human epidermal growth factor receptor 2 (HER2) extracellular domain levels are associated with progression-free survival in patients with HER2-positive metastatic breast cancer receiving lapatinib monotherapy. Cancer 2011, 117:5013-5020.
66. Kostler W.J., Schwab B., Singer C.F., Neumann R., Rucklinger E., Brodowicz T., Tomek S., Niedermayr M., Hejna M., Steger G.G., Krainer M., Wiltschke C., Zielinski C.C. Monitoring of serum Her-2/neu predicts response and progression-free survival to trastuzumab-based treatment in patients with metastatic breast cancer. Clin. Cancer Res. 2004, 10:1618-1624.
67. Molina R., Jo J., Filella X., Zanon G., Farrus B., Munoz M., Latre M.L., Pahisa J., Velasco M., Fernandez P., Estape J., Ballesta A.M. C-erbB-2, CEA and CA 15.3 serum levels in the early diagnosis of recurrence of breast cancer patients. Anticancer Res. 1999, 19:2551-2555.
68. Schondorf T., Hoopmann M., Warm M., Neumann R., Thomas A., Gohring U.J., Eisberg C., Mallmann P. Serologic concentrations of HER-2/neu in breast cancer patients with visceral metastases receiving trastuzumab therapy predict the clinical course. Clin. Chem. 2002, 48:1360-1362.
69. Pectasides D., Gaglia A., Arapantoni-Dadioti P., Bobota A., Valavanis C., Kostopoulou V., Mylonakis N., Karabelis A., Pectasides M., Economopoulos T. HER-2/neu status of primary breast cancer and corresponding metastatic sites in patients with advanced breast cancer treated with trastuzumab-based therapy. Anticancer Res. 2006, 26:647-653.
70. Hayashi N., Nakamura S., Tokuda Y., Yagata H., Yoshida A., Ota H., Hortobagyi G.N., Cristofanilli M., Ueno N.T. Serum HER2 levels determined by two methods in patients with metastatic breast cancer. Int. J. Clin. Oncol. 2012, 17:55-62.
71. Ali S.M., Leitzel K., Lipton A., Carney W.P., Kostler W.J. Value of serum human epidermal growth factor receptor 2 (HER2)/neu testing for early prediction of response to HER2/neu-directed therapies is still an open one and deserves further study in large prospective trials. J. Clin. Oncol. 2009, 27:e273. author reply e274-275.
72. Tse C., Lamy P.J. Clinical utility of serum human epidermal growth factor receptor 2 extracellular domain levels: stop the shilly-shally-it is time for a well-designed, large-scale prospective study. J. Clin. Oncol. 2009, 27:e286-e287.
73. Molina M.A., Codony-Servat J., Albanell J., Rojo F., Arribas J., Baselga J. Trastuzumab (herceptin), a humanized anti-Her2 receptor monoclonal antibody, inhibits basal and activated Her2 ectodomain cleavage in breast cancer cells. Cancer Res. 2001, 61:4744-4749.
74. Vazquez-Martin A., Oliveras-Ferraros C., Cufi S., Del Barco S., Martin-Castillo B., Menendez J.A. Lapatinib, a dual HER1/HER2 tyrosine kinase inhibitor, augments basal cleavage of HER2 extracellular domain (ECD) to inhibit HER2-driven cancer cell growth. J. Cell. Physiol. 2011, 226:52-57.
75. Ardavanis A., Kountourakis P., Kyriakou F., Malliou S., Mantzaris I., Garoufali A., Yiotis I., Scorilas A., Baziotis N., Rigatos G. Trastuzumab plus paclitaxel or docetaxel in HER-2-negative/HER-2 ECD-positive anthracycline- and taxane-refractory advanced breast cancer. Oncologist 2008, 13:361-369.
76. Sandri M.T., Johansson H.A., Zorzino L., Salvatici M., Passerini R., Maisonneuve P., Rocca A., Peruzzotti G., Colleoni M. Serum EGFR and serum HER-2/neu are useful predictive and prognostic markers in metastatic breast cancer patients treated with metronomic chemotherapy. Cancer 2007, 110:509-517.
77. Lipton A., Leitzel K., Ali S.M., Demers L., Harvey H.A., Chaudri-Ross H.A., Evans D., Lang R., Hackl W., Hamer P., Carney W. Serum HER-2/neu conversion to positive at the time of disease progression in patients with breast carcinoma on hormone therapy. Cancer 2005, 104:257-263.
78. Payne R.C., Allard J.W., Anderson-Mauser L., Humphreys J.D., Tenney D.Y., Morris D.L. Automated assay for HER-2/neu in serum. Clin. Chem. 2000, 46:175-182.
79. Loo L., Capobianco J.A., Wu W., Gao X., Shih W.Y., Shih W.H., Pourrezaei K., Robinson M.K., Adams G.P. Highly sensitive detection of HER2 extracellular domain in the serum of breast cancer patients by piezoelectric microcantilevers. Anal. Chem. 2011, 83:3392-3397.
80. Zhang H., Cheng X., Richter M., Greene M.I. A sensitive and high-throughput assay to detect low-abundance proteins in serum. Nat. Med. 2006, 12:473-477.
81. Chang B., Cheng X., Yin S., Pan T., Zhang H., Wong P., Kang S.C., Xiao F., Yan H., Li C., Wolfe L.L., Miller M.W., Wisniewski T., Greene M.I., Sy M.S. Test for detection of disease-associated prion aggregate in the blood of infected but asymptomatic animals. Clin. Vaccine Immunol. 2007, 14:36-43.
82. Kricka L.J. Human anti-animal antibody interferences in immunological assays. Clin. Chem. 1999, 45:942-956.
83. Leach M.F., Aubuchon J.P. False reactivity in GTI Pak Plus ELISA kits due to the presence of anti-mouse antibody in patients' samples. Immunohematology 2003, 19:112-116.
84. Andersen D.C., Koch C., Jensen C.H., Skjodt K., Brandt J., Teisner B. High prevalence of human anti-bovine IgG antibodies as the major cause of false positive reactions in two-site immunoassays based on monoclonal antibodies. J. Immunoassay Immunochem. 2004, 25:17-30.
85. Preissner C.M., O'Kane D.J., Singh R.J., Morris J.C., Grebe S.K. Phantoms in the assay tube: heterophile antibody interferences in serum thyroglobulin assays. J. Clin. Endocrinol. Metab. 2003, 88:3069-3074.
86. Zhang H., Fu T., McGettigan S., Kumar S., Liu S., Speicher D., Schuchter L., Xu X. IL8 and Cathepsin B as Melanoma Serum Biomarkers. Int. J. Mol. Sci. 2011, 12:1505-1518.
87. Morgan B.R., Tarter T.H. Serum heterophile antibodies interfere with prostate specific antigen test and result in over treatment in a patient with prostate cancer. J. Urol. 2001, 166:2311-2312.
88. Levinson S.S., Miller J.J. Towards a better understanding of heterophile (and the like) antibody interference with modern immunoassays. Clin. Chim. Acta 2002, 325:1-15.
89. Klee G.G. Human anti-mouse antibodies. Arch. Pathol. Lab. Med. 2000, 124:921-923.
90. Ismail A.A. A radical approach is needed to eliminate interference from endogenous antibodies in immunoassays. Clin. Chem. 2005, 51:25-26.
91. Reinsberg J. Different efficacy of various blocking reagents to eliminate interferences by human antimouse antibodies with a two-site immunoassay. Clin. Biochem. 1996, 29:145-148.
92. Andersson M., Ronnmark J., Arestrom I., Nygren P.A., Ahlborg N. Inclusion of a non-immunoglobulin binding protein in two-site ELISA for quantification of human serum proteins without interference by heterophilic serum antibodies. J. Immunol. Methods 2003, 283:225-234.
93. Romond E.H., Perez E.A., Bryant J., Suman V.J., Geyer C.E., Davidson N.E., Tan-Chiu E., Martino S., Paik S., Kaufman P.A., Swain S.M., Pisansky T.M., Fehrenbacher L., Kutteh L.A., Vogel V.G., Visscher D.W., Yothers G., Jenkins R.B., Brown A.M., Dakhil S.R., Mamounas E.P., Lingle W.L., Klein P.M., Ingle J.N., Wolmark N. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N. Engl. J. Med. 2005, 353:1673-1684.